1 Min Read
March 23 (Reuters) - Idt Corp
* FDA provides cornerstone pharmaceuticals approval to initiate pivotal study for CPI-613, its metabolism-directed anticancer compound Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.